- Author:
Sewoong KIM
1
;
Min Kyoung KIM
;
Daeyoung OH
;
Sang Hyuk LEE
;
Borah KIM
Author Information
- Publication Type:Review
- Keywords: Induced pluripotent stem cells; Mental disorders; Cellular model; Drug screening
- MeSH: Bipolar Disorder; Dementia; Drug Evaluation, Preclinical; Humans; Induced Pluripotent Stem Cells*; Mental Disorders; Neuroglia; Neurons; Rett Syndrome; Schizophrenia
- From:Psychiatry Investigation 2016;13(1):8-17
- CountryRepublic of Korea
- Language:English
- Abstract: Reprogramming of somatic cells into induced pluripotent stem cells (iPSCs) provides a valuable opportunity to study neurodevelopmental and neurodegenerative psychiatric diseases by offering an unlimited source for patient-specific neuronal and glial cells. The present review focuses on the recent advancements in modeling psychiatric disorders such as Phelan-McDermid syndrome, Timothy syndrome, Rett syndrome, schizophrenia, bipolar disorder, and dementia. The treatment effects identified in studies on iPSCs using known therapeutic compounds are also summarized in this review. Here we discuss validation of cellular models and explore iPSCs as a novel drug screening tool. Although there are several limitations associated with the current methods used to study mental disorders, using iPSCs as a model system provides the advantage of rewinding and reviewing the development and degeneration of human neural cells.